Phaseline

Companies › Immunome

Immunome: clinical trials, targets and expected readouts

5 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AL102
Gamma secretase inhibitor targeting Notch signaling
NOTCH1, NOTCH2, NOTCH3Phase 2DesmoidDec 2026
Varegacestat
Presenilin-1 (PS1) inhibitor; gamma-secretase inhibitor
PSEN1Phase 1HealthyMay 2027
IM-1021
antibody-drug conjugate
–Phase 1Solid MalignanciesMay 2028
IM-1617
antibody-drug conjugate
–Phase 1Colorectal CancerJan 2029
177Lu-IM-3050
FAP-directed radiopharmaceutical
FAPPhase 1Solid MalignanciesDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04871282AL102Phase 2DesmoidOncologyDec 2026
NCT07610005VaregacestatPhase 1HealthyOtherMay 2027
NCT06823167IM-1021Phase 1Solid MalignanciesOncologyMay 2028
NCT07578571IM-1617Phase 1Colorectal CancerOncologyJan 2029
NCT07505771177Lu-IM-3050Phase 1Solid MalignanciesOncologyDec 2029

From the company's SEC filings

Cash and short-term investments of $462m on 2026-09-30; operating cash outflow about $243m a year; runway about 23 months at that burn, to Aug 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PSEN1 (1) NOTCH1 (1) NOTCH2 (1) NOTCH3 (1) FAP (1)

Companies with the same targets

Chengdu New Radiomedicine Technology Avacta Life Sciences Blue Earth Diagnostics GSK SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Novartis Ratio Therapeutics Beijing Biotech SOFIE Philogen

Companies built like this

Cogent Biosciences ORIC Pharmaceuticals Chengdu New Radiomedicine Technology ArriVent BioPharma Olema Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.